Drug Profile
Research programme: psychiatric disorder therapies - AstraZeneca/PsychoGenics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca; PsychoGenics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psychiatric disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Psychiatric-disorders in USA
- 01 Sep 2009 Early research in Psychiatric disorders in USA (unspecified route)